Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 805.31% year-on-year.
Overvalued
The company’s latest PE is 315.43, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 65.17M shares, decreasing 9.44% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 34.18K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.59.